MNOV Logo

MediciNova, Inc. (MNOV) 

NASDAQ
Market Cap
$77.49M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
625 of 776
Rank in Industry
338 of 433

Largest Insider Buys in Sector

MNOV Stock Price History Chart

MNOV Stock Performance

About MediciNova, Inc.

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and …

Insider Activity of MediciNova, Inc.

Over the last 12 months, insiders at MediciNova, Inc. have bought $0 and sold $0 worth of MediciNova, Inc. stock.

On average, over the past 5 years, insiders at MediciNova, Inc. have bought $69,240 and sold $17,077 worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 2,000 shares for transaction amount of $7,240 was made by Matsuda Kazuko (Chief Medical Officer) on 2020‑03‑13.

List of Insider Buy and Sell Transactions, MediciNova, Inc.

2022-11-28Saledirector
6,754
0.0116%
$2.25$15,197-16.35%
2022-11-22Saledirector
218
0.0004%
$2.13$464+5.19%
2022-11-21Saledirector
5,365
0.0112%
$2.18$11,696+4.69%
2022-11-17Saledirector
309
0.0006%
$2.18$674+2.29%
2021-03-11Saledirector
2,354
0.0052%
$7.40$17,420-47.29%
2020-09-15Saledirector
1,000
0.0022%
$5.78$5,780-11.94%
2020-03-13PurchaseChief Medical Officer
2,000
0.0041%
$3.62$7,240+38.71%
2020-03-12PurchasePresident and CEO
20,000
0.0451%
$3.10$62,000+78.59%
2017-08-21Purchasedirector
5,000
0.0148%
$5.17$25,850+71.53%
2017-05-15Purchasedirector
2,000
0.0056%
$5.60$11,200+15.24%
2017-05-12Purchasedirector
48,000
0.1421%
$5.62$269,760+20.44%
2016-09-15Purchasedirector
23,600
0.0662%
$6.44$151,984-10.96%
2016-09-09Purchasedirector
20,000
0.06%
$6.67$133,400-7.75%
2016-07-05SaleVice President
6,600
0.0155%
$6.40$42,240-22.50%
2014-12-10Purchasedirector
24,000
0.1054%
$3.54$84,960+4.48%
2014-11-26Purchasedirector
20,000
0.0812%
$3.07$61,400+11.78%
2014-11-20Purchasedirector
26,000
0.1112%
$3.19$82,940+13.23%
2014-11-19Purchasedirector
10,000
0.04%
$2.86$28,600+18.18%
2014-09-11Purchasedirector
20,000
0.084%
$2.95$59,000+22.68%
2014-09-03Purchasedirector
30,000
0.132%
$2.66$79,698+42.80%

Insider Historical Profitability

12.03%
IWAKI YUICHIPresident and CEO
780683
1.5917%
$1.58150+31.46%
Izumi Tatsuodirector
600000
1.2233%
$1.5851<0.0001%
Matsuda KazukoChief Medical Officer
111746
0.2278%
$1.5810+38.71%
Kalafer Michael EChief Medical Officer
31744
0.0647%
$1.5810
Kobayashi Yutakadirector
25000
0.051%
$1.5890+12.44%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Essex Woodlands Management Inc$1.6M2.261.11M0%+$00.47
BlackRock$1.01M1.42695,420-0.6%-$6,121.91<0.0001
The Vanguard Group$903,833.001.27623,3330%+$0<0.0001
Citigroup$649,538.000.91447,9570%+$0<0.0001
Geode Capital Management$635,080.000.89437,860+0.49%+$3,085.04<0.0001
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.